Abstract | AIMS AND METHODS: RESULTS:
TGF-beta1 was detected in 87% (94/108), HIF-1 alpha in 85% (92/108), and GLUT-1 in 65% (70/108) of colorectal cancers. Not only did TGF-beta1 accumulate in cytoplasm of cancer cells but also there was strong immunoreactivity to TGF-beta1 in adjacent inflammatory cells. GLUT-1 was visualised in a membranous fashion while HIF-1 was expressed in a paranuclear pattern and occasionally in nuclei of malignant cells. Cancer immunoreactivities to TGF-beta1 correlated with HIF-1 alpha (p < 0.001, r = 0.516) and GLUT-1 (p < [corrected] 0.001, r = 0.355) in general and subgroups of different clinicopathological traits. TGF-beta1 expressions of inflammatory infiltrates correlated with longer patient survival (p = 0.05, r = 0.449) and immunoreactivities to HIF-1 alpha of cancer cells (p = 0.008, r = 0.254) particularly in node positive and deeply invading cancers but failed to associate significantly with GLUT-1. CONCLUSIONS: HIF-1 alpha and GLUT-1 could cooperate with TGF-beta1, and TGF-beta1 might mediate cross-talk between the inflammatory environment and tumour with a favourable impact on patient survival.
|
Authors | Mariola Sulkowska, Andrzej Wincewicz, Stanislaw Sulkowski, Mariusz Koda, Luiza Kanczuga-Koda |
Journal | Pathology
(Pathology)
Vol. 41
Issue 3
Pg. 254-60
( 2009)
ISSN: 1465-3931 [Electronic] England |
PMID | 19142800
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- Glucose Transporter Type 1
- HIF1A protein, human
- Hypoxia-Inducible Factor 1, alpha Subunit
- Transforming Growth Factor beta1
|
Topics |
- Biomarkers, Tumor
(analysis)
- Colorectal Neoplasms
(metabolism, mortality)
- Glucose Transporter Type 1
(metabolism)
- Humans
- Hypoxia-Inducible Factor 1, alpha Subunit
(metabolism)
- Immunohistochemistry
- Receptor Cross-Talk
(physiology)
- Transforming Growth Factor beta1
(metabolism)
|